How do nanomedicines enter cells?

Treating from the inside out

Researchers are working on ways to get nanomedicine past the normal barriers that keep drugs from reaching where they need to work inside the body. The central challenge is not just whether a therapy can bind to a target, but whether its delivery system can be taken up by cells and then release the right payload at the right time.

The report focuses on the “inside out” problem: swallowed nanomedicine must survive digestion, cross biological membranes, and enter cells in a form that can function intracellularly. That means scientists are studying the mechanisms of cell entry—such as how different nanoparticle designs are recognized by the body, how they traffic through cellular compartments, and how they can be engineered to trigger drug release after uptake.

Why it matters is straightforward: many of the most effective medical strategies require action inside cells. Deliveries that only act outside cells may work for some conditions, but they can fall short when diseases are driven by intracellular processes (for example, pathways related to metabolism, inflammation, or genetic disorders).

The practical implication is that improving nanomedicine delivery could broaden the range of treatable conditions. It could also reduce the dose required and improve safety by limiting off-target exposure—two goals that often come down to whether delivery systems can reliably reach intracellular sites.

Overall, the work represents a shift from designing “just a drug” toward designing coordinated drug-and-delivery systems that can navigate the body’s natural defenses and then act where the biology demands.